23 results
6-K
CNTB
Connect Biopharma Holdings Ltd
5 Jan 22
Current report (foreign)
5:24pm
occurred during the COVID-19 pandemic and the patient population recruited had a markedly lower AD disease severity and higher patient discontinuation … withdrawing consent or patients being lost to follow-up, and it is likely that movement restrictions related to the COVID-19 pandemic contributed
6-K
EX-99.1
CNTB
Connect Biopharma Holdings Ltd
5 Jan 22
Current report (foreign)
5:24pm
Phase 2b trial occurred during the COVID-19 pandemic and the patient population recruited had a markedly lower AD disease severity and higher patient … to patients withdrawing consent or patients being lost to follow-up, and it is likely that movement restrictions related to the COVID-19 pandemic
F-1
EX-10.14
CNTB
Connect Biopharma Holdings Ltd
26 Feb 21
Registration statement (foreign)
4:56pm
restrictions are lifted post pandemic and before your relocation to San Diego, you may be required to be onsite in San Diego up to at least one week per … over relocation, travel restrictions related to the ongoing Covid-19 pandemic and a reasonable period to find suitable relocation services that can
6-K
CNTB
Connect Biopharma Holdings Ltd
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
was started during the
worldwide COVID-19 pandemic and COVID-19 adverse events were noted across all treatment groups. No new safety signals were
6-K
EX-99.2
CNTB
Connect Biopharma Holdings Ltd
5 Jan 22
Current report (foreign)
5:24pm
of COVID-19 pandemic potentially contributing to lower opportunities for disease flaring during movement restrictions (e.g. less exposure to environmental … to Placebo efficacy responses / ¯ Efficacy responses for active treatment groups 3 2. Higher treatment discontinuations due to the COVID-19 pandemic movement
20-F
ss73gpcx8 26uj334y
31 Mar 22
Annual report (foreign)
4:33pm
6-K
EX-99.1
4saoswq kj5ncq
19 Nov 21
Primary endpoint met with all three CBP-201 arms achieving significant improvements
8:00am
6-K
EX-99.1
qcl5bt
12 Dec 23
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
6:10am
F-1/A
cbqthtc7jwu
18 Mar 21
Registration statement (foreign) (amended)
6:15am
6-K
EX-99.1
q8owl8g4785annz8c
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
F-1
9xnn59zpqhixusxu76
26 Feb 21
Registration statement (foreign)
4:56pm
6-K
EX-99.3
39kty3oa43jka
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
424B4
x2xyhtp4mgow 6xveln
19 Mar 21
Prospectus supplement with pricing info
4:49pm
DRS/A
karki6j
26 Jan 21
Draft registration statement (amended)
12:00am
DRS
qaaqxnhk9
17 Dec 20
Draft registration statement
12:00am
F-1/A
rtui9 541
12 Mar 21
Registration statement (foreign) (amended)
5:02pm
6-K
io9 kuceqo3
13 Sep 22
Connect Biopharma Reports First Half 2022 Financial Results
4:47pm
6-K
EX-99.1
v85tb1es6fq
31 Aug 21
Index to the Unaudited Interim Condensed Consolidated Financial Statements
4:16pm
6-K
EX-99.2
imqp i7x5
3 Jun 21
Development program exploring the potential of CBP-174 in the treatment of chronic inflammatory pruritus
6:04am